Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Krystal Biotech Price Performance

KRYS traded down $9.76 on Friday, reaching $163.64. 541,492 shares of the company’s stock were exchanged, compared to its average volume of 322,730. The stock has a market cap of $4.71 billion, a PE ratio of 92.66 and a beta of 0.80. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34. The stock’s fifty day moving average price is $181.54 and its 200-day moving average price is $184.87.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the business earned ($0.67) earnings per share. The business’s revenue was up 879.9% compared to the same quarter last year. As a group, research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital restated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Thursday. Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $202.86.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after buying an additional 94 shares during the period. Louisiana State Employees Retirement System purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $2,296,000. EFG Asset Management North America Corp. raised its position in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after acquiring an additional 103,928 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).